Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar
Background: Tuberculosis is considered the second most common cause of death due to infectious agent. The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-do...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Format: | article |
| Published: |
2017
|
| Online Access: | http://hdl.handle.net/10725/6783 http://dx.doi.org/10.1186/s12879-017-2231-1 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2231-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513480692858880 |
|---|---|
| author | Al-Shaer, Mohammad H. |
| author2 | Mansour, Hanine Elewa, Hazem Salameh, Pascale Iqbal, Fatima |
| author2_role | author author author author |
| author_facet | Al-Shaer, Mohammad H. Mansour, Hanine Elewa, Hazem Salameh, Pascale Iqbal, Fatima |
| author_role | author |
| dc.creator.none.fl_str_mv | Al-Shaer, Mohammad H. Mansour, Hanine Elewa, Hazem Salameh, Pascale Iqbal, Fatima |
| dc.date.none.fl_str_mv | 2017-12-13T12:49:12Z 2017-12-13T12:49:12Z 2017 2017-12-13 |
| dc.identifier.none.fl_str_mv | 1471-2334 http://hdl.handle.net/10725/6783 http://dx.doi.org/10.1186/s12879-017-2231-1 Al-Shaer, M. H., Mansour, H., Elewa, H., Salameh, P., & Iqbal, F. (2017). Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC infectious diseases, 17(1), 1-6. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2231-1 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | BMC Infectious Diseases |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Background: Tuberculosis is considered the second most common cause of death due to infectious agent. The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC). To date, no studies have compared both regimens in Qatar. We aim to evaluate the safety and effectiveness of FDC and ST regimen for treating PTB, in addition to comparing safety and efficacy of FDC and ST regimens in patients with diabetes treated for TB. Methods: A retrospective observational study was conducted in two general hospitals in Qatar. Patients diagnosed with PTB received anti-tuberculosis medications (either as FDC or ST) administered by the nurse. Sputum smears were tested weekly. We assessed the time to negative sputum smear and incidence of adverse events among FDC and ST groups. Results: The study included 148 patients. FDC was used in 90 patients (61%). Effectiveness was not different between FDC and ST regimens as shown by mean time to sputum conversion (29.9 ± 18.3 vs. 35.6 ± 23 days, p = 0.12). Similarly, there was no difference in the incidence of adverse events, except for visual one that was higher in ST group. Among the 33 diabetic patients, 19 received the FDC and had faster sputum conversion compared to those who received ST (31 ± 12 vs. 49.4 ± 30.9 days, p = 0.05). Overall, diabetic patients needed longer time for sputum conversion and had more hepatotoxic and gastric adverse events compared to non-diabetics. Conclusion: ST group had higher visual side effects compared to FDC. FDC may be more effective in diabetic patients; however, further studies are required to confirm such finding. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_8ca55cb71db49cb7d37a89a78eeda4b8 |
| identifier_str_mv | 1471-2334 Al-Shaer, M. H., Mansour, H., Elewa, H., Salameh, P., & Iqbal, F. (2017). Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC infectious diseases, 17(1), 1-6. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/6783 |
| publishDate | 2017 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in QatarAl-Shaer, Mohammad H.Mansour, HanineElewa, HazemSalameh, PascaleIqbal, FatimaBackground: Tuberculosis is considered the second most common cause of death due to infectious agent. The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC). To date, no studies have compared both regimens in Qatar. We aim to evaluate the safety and effectiveness of FDC and ST regimen for treating PTB, in addition to comparing safety and efficacy of FDC and ST regimens in patients with diabetes treated for TB. Methods: A retrospective observational study was conducted in two general hospitals in Qatar. Patients diagnosed with PTB received anti-tuberculosis medications (either as FDC or ST) administered by the nurse. Sputum smears were tested weekly. We assessed the time to negative sputum smear and incidence of adverse events among FDC and ST groups. Results: The study included 148 patients. FDC was used in 90 patients (61%). Effectiveness was not different between FDC and ST regimens as shown by mean time to sputum conversion (29.9 ± 18.3 vs. 35.6 ± 23 days, p = 0.12). Similarly, there was no difference in the incidence of adverse events, except for visual one that was higher in ST group. Among the 33 diabetic patients, 19 received the FDC and had faster sputum conversion compared to those who received ST (31 ± 12 vs. 49.4 ± 30.9 days, p = 0.05). Overall, diabetic patients needed longer time for sputum conversion and had more hepatotoxic and gastric adverse events compared to non-diabetics. Conclusion: ST group had higher visual side effects compared to FDC. FDC may be more effective in diabetic patients; however, further studies are required to confirm such finding.PublishedN/A2017-12-13T12:49:12Z2017-12-13T12:49:12Z20172017-12-13Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1471-2334http://hdl.handle.net/10725/6783http://dx.doi.org/10.1186/s12879-017-2231-1Al-Shaer, M. H., Mansour, H., Elewa, H., Salameh, P., & Iqbal, F. (2017). Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC infectious diseases, 17(1), 1-6.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2231-1enBMC Infectious Diseasesinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/67832022-04-06T11:52:49Z |
| spellingShingle | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar Al-Shaer, Mohammad H. |
| status_str | publishedVersion |
| title | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar |
| title_full | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar |
| title_fullStr | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar |
| title_full_unstemmed | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar |
| title_short | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar |
| title_sort | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar |
| url | http://hdl.handle.net/10725/6783 http://dx.doi.org/10.1186/s12879-017-2231-1 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2231-1 |